Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease Portfolio News / By Karina Tin March 1, 2021 Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease Read More »
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results Portfolio News / By Karina Tin February 24, 2021 Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin February 16, 2021 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update Read More »
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin February 8, 2021 Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More »
Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries Portfolio News / By Karina Tin February 2, 2021 Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries Read More »
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders Portfolio News / By Karina Tin January 21, 2021 Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders Read More »
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology Portfolio News / By Karina Tin January 12, 2021 NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Portfolio News / By Karina Tin January 11, 2021 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones Read More »
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Portfolio News / By Karina Tin January 7, 2021 eFFECTOR Appoints Mike Byrnes as Chief Financial Officer Read More »
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Portfolio News / By Karina Tin January 7, 2021 Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer Read More »
